Sirolimus Gel for Angiokeratoma

(LOTU Trial)

This trial tests a new gel called PTX-022 (sirolimus gel) to determine its safety and effectiveness in treating angiokeratomas, which are small, dark skin spots caused by widened blood vessels. Researchers aim to find out if this gel can reduce or eliminate these spots. Individuals diagnosed with angiokeratomas who can meet the trial requirements may be suitable candidates for this study. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, providing participants an opportunity to contribute to significant medical advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Studies have shown that PTX-022, a gel containing 3.9% sirolimus, is generally safe for use. Most people tolerate this gel well, though some side effects can occur. The most common issue is irritation at the application site, reported in about 30.9% of cases. Other frequent side effects include dry skin (27.7%) and acne (20.2%). Less common issues were eye irritation and itching, each occurring in 8.5% of cases.

Sirolimus Gel, under study for treating angiokeratoma, is unique because it uses sirolimus, an mTOR inhibitor, to target the root cause of the condition. Unlike standard treatments such as laser therapy or cryotherapy, which primarily focus on removing visible lesions, sirolimus gel works at the cellular level to potentially reduce the growth of the lesions by interfering with abnormal cell proliferation. Researchers are excited because this topical treatment could offer a less invasive and more targeted approach, leading to better management of angiokeratoma with fewer side effects.

Research has shown that sirolimus gel, which participants in this trial will receive, may help treat skin conditions like angiokeratomas. In studies, individuals with conditions such as TSC (tuberous sclerosis complex), which causes facial skin issues, found the gel safe and effective over time. The gel targets abnormal blood vessels, helping to normalize them and reduce skin lesions. Additionally, sirolimus gel has demonstrated good results in treating other non-cancerous skin conditions, suggesting it might also work well for angiokeratomas.¹²³⁶⁷